TEVA

Prezzo Teva Pharmaceutical-Sp

Closed
TEVA
$0
+$0(0,00%)
Nessun dato

*Data last updated: 2026-04-29 05:09 (UTC+8)

As of 2026-04-29 05:09, Teva Pharmaceutical-Sp (TEVA) is priced at $0, with a total market cap of $36,81B, a P/E ratio of 25,43, and a dividend yield of 0,00%. Today, the stock price fluctuated between $0 and $0. The current price is 0,00% above the day's low and 0,00% below the day's high, with a trading volume of 8,38M. Over the past 52 weeks, TEVA has traded between $0 to $0, and the current price is 0,00% away from the 52-week high.

TEVA Key Stats

Yesterday's Close$31
Market Cap$36,81B
Volume8,38M
P/E Ratio25,43
Dividend Yield (TTM)0,00%
Dividend Amount$0
Diluted EPS (TTM)1,23
Net Income (FY)$1,41B
Revenue (FY)$17,25B
Earnings Date2026-04-29
EPS Estimate0,50
Revenue Estimate$3,78B
Shares Outstanding1,17B
Beta (1Y)0.764
Ex-Dividend Date2017-11-27
Dividend Payment Date2017-12-12

About TEVA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEORichard D. Francis
HeadquartersTel Aviv,None,IL
Employees (FY)34,00K
Average Revenue (1Y)$507,55K
Net Income per Employee$41,47K

Teva Pharmaceutical-Sp (TEVA) FAQ

What's the stock price of Teva Pharmaceutical-Sp (TEVA) today?

x
Teva Pharmaceutical-Sp (TEVA) is currently trading at $0, with a 24h change of 0,00%. The 52-week trading range is $0–$0.

What are the 52-week high and low prices for Teva Pharmaceutical-Sp (TEVA)?

x

What is the price-to-earnings (P/E) ratio of Teva Pharmaceutical-Sp (TEVA)? What does it indicate?

x

What is the market cap of Teva Pharmaceutical-Sp (TEVA)?

x

What is the most recent quarterly earnings per share (EPS) for Teva Pharmaceutical-Sp (TEVA)?

x

Should you buy or sell Teva Pharmaceutical-Sp (TEVA) now?

x

What factors can affect the stock price of Teva Pharmaceutical-Sp (TEVA)?

x

How to buy Teva Pharmaceutical-Sp (TEVA) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

Hot Posts su Teva Pharmaceutical-Sp (TEVA)

NightAirdropper

NightAirdropper

03-28 05:54
当前,外资机构正悄然加大对中国医药股的配置力度。近日披露的上市公司年报数据显示,高盛、瑞银、巴克莱银行等多家外资巨头去年四季度新进多只医药股前十大流通股股东名单,布局横跨创新药、中药、医疗器械等多个细分领域。与此同时,百济神州、华大基因等多家医药上市公司今年以来也密集迎来外资机构调研。   数据显示,瑞银集团去年四季度新进新诺威前十大流通股股东名单,持股数量为687.7万股。东北证券研报显示,新诺威主营业务覆盖创新药、原料药和保健食品板块。在创新药板块,公司全面布局ADC、单抗和mRNA疫苗领域,目前已有恩朗苏拜单抗注射液和注射用奥马珠单抗注射液等多款产品在国内获批上市,覆盖肿瘤和自免领域的核心适应症。   特一药业则同时获得高盛和瑞银集团的青睐,二者在去年四季度新进成为特一药业前十大流通股股东,截至去年四季度末持股数量分别为224万股、171万股。资料显示,特一药业是一家专注于中成药、化学制剂及原料药研发、生产和销售的医药制造企业。   去年第四季度,黄山胶囊获得巴克莱银行与高盛抱团买入,两家机构双双新进该公司前十大流通股股东名单。截至去年四季度末,巴克莱银行与高盛的持股数量分别为131.7万股和113.5万股。   高盛和瑞银集团去年四季度新进成为合富中国的前十大流通股股东,截至去年四季度末,二者的持股数量分别为50.7万股、37.6万股。   今年以来,外资机构仍在积极调研A股医药上市公司。据WIND统计,截至3月24日,今年以来百济神州获得81家外资机构调研,在所有获得外资机构调研的A股公司中排名首位。此外,华大基因、爱博医疗、蓝帆医疗、新产业、康希诺、普洛药业等医药领域上市公司,均迎来多家外资机构调研。   沪上一位第三方分析人士对上证报记者表示,从配置结构来看,外资在医药板块的配置上横跨中药、医药制造和部分成长型医药标的,呈现出“防御+成长”的双线布局特征。这种配置思路既反映了外资对中国医药产业长期发展的信心,也体现出对当前市场环境下“确定性”与“成长性”的平衡考量。   “一方面,中药龙头公司受益于政策支持和消费升级,业绩增长稳健,具备较强的抗周期能力;另一方面,以创新药为代表的成长型标的则承载着产业升级和自主可控的长期逻辑,潜在成长空间更大。”该人士补充。   一位外资基金经理在接受上证报记者采访时表示,当前A股医药板块具备丰富的阿尔法机会。他关注到,CXO板块订单拐点已逐步确立,产业链有望迎来业绩与估值的双重修复;在医疗器械、中药等细分领域,部分具备技术壁垒、经营稳健且在集采后企稳的企业,也具备较好的防御价值与估值吸引力。   “总体而言,我们对中国医药产业的中长期发展保持积极看法,当前阶段更倾向于通过精选个股、把握业绩兑现节奏来构建组合。”该基金经理称。
0
0
0
0